High concentration formulation developability approaches and considerations.

Zarzar, Jonathan; Khan, Tarik; Bhagawati, Maniraj; Weiche, Benjamin; Sydow-Andersen, Jasmin; Alavattam, Sreedhara

Zarzar, Jonathan; Khan, Tarik; Bhagawati, Maniraj; Weiche, Benjamin; Sydow-Andersen, Jasmin; Alavattam, Sreedhara.

Afiliação

Zarzar J; Pharmaceutical Development, Genentech Inc, South San Francisco, CA, USA.
Khan T; Pharma Technical Development Europe, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Bhagawati M; Large Molecule Research, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany.
Weiche B; Large Molecule Research, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany.
Sydow-Andersen J; Large Molecule Research, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany.
Alavattam S; Pharmaceutical Development, Genentech Inc, South San Francisco, CA, USA.

MAbs ; 15(1): 2211185, 2023.

Article em En | MEDLINE | ID: mdl-37191233

Assuntos

Desenvolvimento de Medicamentos; Preparações Farmacêuticas/química; Desenvolvimento de Medicamentos/métodos; Viscosidade

Palavras-chave

Aggregation; developability; high concentration formulations; in-silico; physical instability; subcutaneous administration; viscosity

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desenvolvimento de Medicamentos Tipo de estudo: Prognostic_studies Idioma: En Revista: MAbs Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google